Cargando…

Immunization with a mucosal, post-fusion F/G protein-based polyanhydride nanovaccine protects neonatal calves against BRSV infection

Human respiratory syncytial virus (HRSV) is a leading cause of death in young children and there are no FDA approved vaccines. Bovine RSV (BRSV) is antigenically similar to HRSV, and the neonatal calf model is useful for evaluation of HRSV vaccines. Here, we determined the efficacy of a polyanhydrid...

Descripción completa

Detalles Bibliográficos
Autores principales: Maina, Teresia W., Grego, Elizabeth A., Broderick, Scott, Sacco, Randy E., Narasimhan, Balaji, McGill, Jodi L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289034/
https://www.ncbi.nlm.nih.gov/pubmed/37359514
http://dx.doi.org/10.3389/fimmu.2023.1186184
_version_ 1785062197726019584
author Maina, Teresia W.
Grego, Elizabeth A.
Broderick, Scott
Sacco, Randy E.
Narasimhan, Balaji
McGill, Jodi L.
author_facet Maina, Teresia W.
Grego, Elizabeth A.
Broderick, Scott
Sacco, Randy E.
Narasimhan, Balaji
McGill, Jodi L.
author_sort Maina, Teresia W.
collection PubMed
description Human respiratory syncytial virus (HRSV) is a leading cause of death in young children and there are no FDA approved vaccines. Bovine RSV (BRSV) is antigenically similar to HRSV, and the neonatal calf model is useful for evaluation of HRSV vaccines. Here, we determined the efficacy of a polyanhydride-based nanovaccine encapsulating the BRSV post-fusion F and G glycoproteins and CpG, delivered prime-boost via heterologous (intranasal/subcutaneous) or homologous (intranasal/intranasal) immunization in the calf model. We compared the performance of the nanovaccine regimens to a modified-live BRSV vaccine, and to non-vaccinated calves. Calves receiving nanovaccine via either prime-boost regimen exhibited clinical and virological protection compared to non-vaccinated calves. The heterologous nanovaccine regimen induced both virus-specific cellular immunity and mucosal IgA, and induced similar clinical, virological and pathological protection as the commercial modified-live vaccine. Principal component analysis identified BRSV-specific humoral and cellular responses as important correlates of protection. The BRSV-F/G CpG nanovaccine is a promising candidate vaccine to reduce RSV disease burden in humans and animals.
format Online
Article
Text
id pubmed-10289034
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102890342023-06-24 Immunization with a mucosal, post-fusion F/G protein-based polyanhydride nanovaccine protects neonatal calves against BRSV infection Maina, Teresia W. Grego, Elizabeth A. Broderick, Scott Sacco, Randy E. Narasimhan, Balaji McGill, Jodi L. Front Immunol Immunology Human respiratory syncytial virus (HRSV) is a leading cause of death in young children and there are no FDA approved vaccines. Bovine RSV (BRSV) is antigenically similar to HRSV, and the neonatal calf model is useful for evaluation of HRSV vaccines. Here, we determined the efficacy of a polyanhydride-based nanovaccine encapsulating the BRSV post-fusion F and G glycoproteins and CpG, delivered prime-boost via heterologous (intranasal/subcutaneous) or homologous (intranasal/intranasal) immunization in the calf model. We compared the performance of the nanovaccine regimens to a modified-live BRSV vaccine, and to non-vaccinated calves. Calves receiving nanovaccine via either prime-boost regimen exhibited clinical and virological protection compared to non-vaccinated calves. The heterologous nanovaccine regimen induced both virus-specific cellular immunity and mucosal IgA, and induced similar clinical, virological and pathological protection as the commercial modified-live vaccine. Principal component analysis identified BRSV-specific humoral and cellular responses as important correlates of protection. The BRSV-F/G CpG nanovaccine is a promising candidate vaccine to reduce RSV disease burden in humans and animals. Frontiers Media S.A. 2023-06-09 /pmc/articles/PMC10289034/ /pubmed/37359514 http://dx.doi.org/10.3389/fimmu.2023.1186184 Text en Copyright © 2023 Maina, Grego, Broderick, Sacco, Narasimhan and McGill https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Maina, Teresia W.
Grego, Elizabeth A.
Broderick, Scott
Sacco, Randy E.
Narasimhan, Balaji
McGill, Jodi L.
Immunization with a mucosal, post-fusion F/G protein-based polyanhydride nanovaccine protects neonatal calves against BRSV infection
title Immunization with a mucosal, post-fusion F/G protein-based polyanhydride nanovaccine protects neonatal calves against BRSV infection
title_full Immunization with a mucosal, post-fusion F/G protein-based polyanhydride nanovaccine protects neonatal calves against BRSV infection
title_fullStr Immunization with a mucosal, post-fusion F/G protein-based polyanhydride nanovaccine protects neonatal calves against BRSV infection
title_full_unstemmed Immunization with a mucosal, post-fusion F/G protein-based polyanhydride nanovaccine protects neonatal calves against BRSV infection
title_short Immunization with a mucosal, post-fusion F/G protein-based polyanhydride nanovaccine protects neonatal calves against BRSV infection
title_sort immunization with a mucosal, post-fusion f/g protein-based polyanhydride nanovaccine protects neonatal calves against brsv infection
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289034/
https://www.ncbi.nlm.nih.gov/pubmed/37359514
http://dx.doi.org/10.3389/fimmu.2023.1186184
work_keys_str_mv AT mainateresiaw immunizationwithamucosalpostfusionfgproteinbasedpolyanhydridenanovaccineprotectsneonatalcalvesagainstbrsvinfection
AT gregoelizabetha immunizationwithamucosalpostfusionfgproteinbasedpolyanhydridenanovaccineprotectsneonatalcalvesagainstbrsvinfection
AT broderickscott immunizationwithamucosalpostfusionfgproteinbasedpolyanhydridenanovaccineprotectsneonatalcalvesagainstbrsvinfection
AT saccorandye immunizationwithamucosalpostfusionfgproteinbasedpolyanhydridenanovaccineprotectsneonatalcalvesagainstbrsvinfection
AT narasimhanbalaji immunizationwithamucosalpostfusionfgproteinbasedpolyanhydridenanovaccineprotectsneonatalcalvesagainstbrsvinfection
AT mcgilljodil immunizationwithamucosalpostfusionfgproteinbasedpolyanhydridenanovaccineprotectsneonatalcalvesagainstbrsvinfection